The UK Competition and Markets Authority fines pharmaceutical companies for pay-for-delay deals (GSK)

UK Antitrust Watchdog slaps $65 million fine on Pharma Companies in UK’s first pay-for-delay case* On 12 February 2016, the Competition and Markets Authority (“CMA”), UK’s competition regulator, fined a number of pharma companies for anti-competitive conduct and agreements in relation to the supply of paroxetine (an anti-depressant drug). The anti-competitive conduct dates back to 2001, when pharmaceutical producers including Alpharma Limited (“Alpharma”) and Generics UK Limited (“GUK”) were preparing to launch their generic versions of paroxetine in the UK. At the time GlaxoSmithKline plc (“GSK”) held certain patents in relation to paroxetine and commercialised a branded version of the drug, Seroxat, which was a “blockbuster” product with annual sales over $130 million in the UK. GSK

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Constantine Cannon (London)
  • Constantine Cannon (London)

Quotation

Richard Pike, Irene Fraile, The UK Competition and Markets Authority fines pharmaceutical companies for pay-for-delay deals (GSK), 12 February 2016, e-Competitions Bulletin February 2016, Art. N° 80279

Visites 213

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues